Autotelic Bio Inc.

Autotelic Bio Inc., a **clinical stage pharmaceutical company** founded in **2015** in **South Korea**, is making strides in the field of RNA therapeutics. The company's proprietary RNA interference (RNAi) ASO platform, **ASODE & CATs (Conjugated ASO Targeting Solution)**, sets it apart by enabling selective targeting and precise optimization of Antisense Oligonucleotide (ASO) therapies. This innovative approach holds the promise of delivering greater efficacy, safety, and tolerability compared to other RNAi medicines. With a focus on **Immuno-oncology, IPF**, and the development of **FDCs with synergy effect**, Autotelic Bio is positioning itself as a key player in tackling pressing medical needs. The company recently secured a substantial **KRW15.50B Series B investment** on **28 March 2022**, with notable investors including **Stonebridge Ventures, UTC 2019 BioVentureFund, LSK Investment, Sejong Venture Partners, Woori Bank, JB Ventures,** and **DT Investments**. Autotelic Bio Inc.'s commitment to advancing RNA therapeutics and its impressive funding round make it a company to watch in the biotechnology and pharmaceutical industries.